AU2007254950A1 - Methods, compositions, and kits for treating Shiga toxin associated conditions - Google Patents

Methods, compositions, and kits for treating Shiga toxin associated conditions Download PDF

Info

Publication number
AU2007254950A1
AU2007254950A1 AU2007254950A AU2007254950A AU2007254950A1 AU 2007254950 A1 AU2007254950 A1 AU 2007254950A1 AU 2007254950 A AU2007254950 A AU 2007254950A AU 2007254950 A AU2007254950 A AU 2007254950A AU 2007254950 A1 AU2007254950 A1 AU 2007254950A1
Authority
AU
Australia
Prior art keywords
chimeric anti
antibodies
stx2
day
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007254950A
Other languages
English (en)
Inventor
Mariam Mehran
Angela Melton-Celsa
Alison O'brien
Marc Riviere
Claire Thunning Roberson
Janique Sam-Pan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thallion Pharmaceuticals Inc
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Thallion Pharmaceuticals Inc
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thallion Pharmaceuticals Inc, Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Thallion Pharmaceuticals Inc
Publication of AU2007254950A1 publication Critical patent/AU2007254950A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007254950A 2006-05-31 2007-05-31 Methods, compositions, and kits for treating Shiga toxin associated conditions Abandoned AU2007254950A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80946406P 2006-05-31 2006-05-31
US60/809,464 2006-05-31
PCT/US2007/012797 WO2007143004A2 (en) 2006-05-31 2007-05-31 Methods, compositions, and kits for treating shiga toxin associated conditions

Publications (1)

Publication Number Publication Date
AU2007254950A1 true AU2007254950A1 (en) 2007-12-13

Family

ID=38802032

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007254950A Abandoned AU2007254950A1 (en) 2006-05-31 2007-05-31 Methods, compositions, and kits for treating Shiga toxin associated conditions

Country Status (6)

Country Link
US (1) US20120195891A1 (https=)
EP (2) EP2545936A3 (https=)
JP (1) JP2009538916A (https=)
AU (1) AU2007254950A1 (https=)
CA (1) CA2652999A1 (https=)
WO (1) WO2007143004A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
US20130195851A1 (en) * 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
RU2732155C1 (ru) * 2019-09-24 2020-09-11 Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) Гуманизированное антитело или его антигенсвязывающий фрагмент (Fab) против шига-токсинов первого и/или второго типов (варианты), композиция для лечения токсических состояний, вызванных энтерогеморрагической кишечной палочкой, содержащая указанные антитела и/или Fab

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
WO2006030883A1 (ja) * 2004-09-17 2006-03-23 Hamamatsu Foundation For Science And Technology Promotion モノクローナル抗体の製造方法
ES2532985T3 (es) * 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga

Also Published As

Publication number Publication date
EP2545936A2 (en) 2013-01-16
US20120195891A1 (en) 2012-08-02
EP2035037A4 (en) 2010-03-31
WO2007143004A2 (en) 2007-12-13
EP2035037A2 (en) 2009-03-18
CA2652999A1 (en) 2007-12-13
JP2009538916A (ja) 2009-11-12
WO2007143004A3 (en) 2008-03-27
EP2545936A3 (en) 2013-02-20

Similar Documents

Publication Publication Date Title
US20120195891A1 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
JP6694269B2 (ja) Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体
JP7823117B2 (ja) 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与
AU2004204834B2 (en) Methods for reducing mortality associated with acute myocardial infarction
JP5954916B1 (ja) Ｉｌ−３１アンタゴニストを有効成分として含有する、アトピー性皮膚炎の予防用及び／又は治療用医薬組成物
JP6278536B2 (ja) 関節炎治療
CN100435806C (zh) 作为毒素结合剂和抗菌试剂的阴离子聚合物
US20140161906A1 (en) Use of angiogenesis antagonists in conditions of abnormal venous proliferation
US11732049B2 (en) Methods of reducing or lowering blood glucose levels in a human subject by administering an antibody that specifically binds human glucagon receptor
CN112996561A (zh) 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用
US20090258010A1 (en) Methods, compositions, and kits for treating shiga toxin associated conditions
JP2002513398A (ja) フィブロネクチン結合タンパク質組成物および使用法
CN113474363A (zh) 用于降低体重和/或减少食物摄取量的gdf15类似物和方法
WO2022036151A1 (en) Dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
EP4181922A1 (en) Methods of using factor b inhibitors
AU2006268045A1 (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
CN114225024A (zh) 一种用于治疗疾病的益生菌药物或保健品
HK40055105A (en) Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
EA043233B1 (ru) ДОЗИРОВАНИЕ И ВВЕДЕНИЕ АНТИТЕЛ ПРОТИВ C5 ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ С ПАРОКСИЗМАЛЬНОЙ НОЧНОЙ ГЕМОГЛОБИНУРИЕЙ (PNH) И АТИПИЧНЫМ ГЕМОЛИТИКО-УРЕМИЧЕСКИМ СИНДРОМОМ (aHUS)
JPS58105916A (ja) 癌治療剤
HK1187260A (en) Treatment for dermatological pathologies

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application